Correction: Assessment and Management of Sleep Disturbance in Cirrhosis
The article Assessment and Management of Sleep Disturbance in Cirrhosis, written by Chiara Formentin, Maria Garrido, and Sara Montagnese, was originally published electronically on the publisher ’s internet portal (currently SpringerLink) on 13 February 2018 without open access. (Source: Current Hepatitis Reports)
Source: Current Hepatitis Reports - May 23, 2018 Category: Infectious Diseases Source Type: research
Management of Autoimmune Hepatitis Patients Refractory to or Intolerant of Standard Therapies
AbstractPurpose of ReviewAutoimmune hepatitis is a progressive T cell-dependent inflammatory process characterized by elevated autoantibodies, serum globulins, and interface hepatitis. Pharmacologic treatment focuses on achievement of complete biochemical remission. The goal of this paper is to describe the unique features that guide treatment in difficult-to-control cases of autoimmune hepatitis.Recent FindingsRecently published retrospective reviews have noted the efficacy of multiple second- and third-line agents in the treatment of autoimmune hepatitis. There has been no widely accepted approach regarding which agents ...
Source: Current Hepatitis Reports - May 16, 2018 Category: Infectious Diseases Source Type: research
Ethnic and Racial Differences in Autoimmune Liver Diseases
AbstractPurpose of the reviewTo discuss the ethnic and racial disparities observed in patients with autoimmune liver diseases, with special focus on epidemiology, patterns of inheritance, clinical presentation, and outcomes.Recent findingsBlack, Hispanics, and Asians with autoimmune hepatitis appear to have more aggressive clinical features, poorer initial response to standard therapy, and higher rates of complications including hepatocellular carcinoma, with worse survival than their White counterparts. African American and Hispanic patients with primary biliary cholangitis have more advanced disease at presentation and H...
Source: Current Hepatitis Reports - April 26, 2018 Category: Infectious Diseases Source Type: research
Expanding Capacity to Treat Hepatitis C: Overcoming Barriers and New Innovations
AbstractChronic hepatitis C virus (HCV) infection remains a global public health burden and is associated with significant morbidity and mortality. Despite significant advances in the safety and efficacy of antiviral therapy since 2014 due to the rise of oral direct acting antiviral (DAA) regimens, ongoing deficits persist across the care cascade in the USA which will limit success in achieving the objectives of the US National Academies of Sciences, Engineering, and Medicine and the World Health Organization to eliminate chronic HCV in the USA and worldwide. In this review, we discuss the critical role of expanding treatm...
Source: Current Hepatitis Reports - April 17, 2018 Category: Infectious Diseases Source Type: research
The Newest Direct-Acting Antiviral Agents: the Final Chapter in DAA Development
AbstractPurpose of the ReviewHepatitis C virus (HCV) therapy has improved dramatically in recent years; however, small clinical gaps remained. The recent approval of the final two antiviral regimens likely to come to clinical use addresses most unmet medical needs. The clinical trial data supporting the approval of these regimens is reviewed, highlighting how they address outstanding clinical needs and noting the very few gaps that still remain.Recent FindingsThe approval of sofosbuvir/velpatasvir/voxilaprevir provides an excellent salvage regimen for patients who have failed prior treatment with direct antiviral agents. A...
Source: Current Hepatitis Reports - April 7, 2018 Category: Infectious Diseases Source Type: research
